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Summary 
The outcome of refractory/relapsed patients with pediatric T-cell acute 
lymphoblastic leukemia (T-ALL) is extremely poor1, the genetic basis of which 
remains poorly understood.  Here we report a comprehensive profiling of 121 cases 
with pediatric T-ALL using transcriptome/targeted-capture sequencing, through 
which we identified novel recurrent gene fusions involving SPI1 
(STMN1-SPI1/TCF7-SPI1).  SPI1 fusion-positive cases, accounting for 3.9% (7/181) of 
pediatric T-ALL examined, showed a double-negative (DN; CD4 Ѹ CD8 Ѹ ) or CD8 
single-positive (SP) phenotype and had a uniformly poor overall survival.  These 
cases represent a subset of pediatric T-ALL distinguishable from the known T-ALL 
subsets2, in terms of expression of genes involved in T-cell precommitment, 
establishment of T-cell identity, and post β-selection and of mutational profile.  SPI1 
fusions retained transcriptional activities, and when constitutively expressed in 
mouse stem/progenitor cells, they induced an enhanced cell proliferation and a 
maturation block.  Our findings highlight a unique role of SPI1 fusions in high-risk 
pediatric T-ALL. 
 We first searched recurrent gene fusions based on RNA sequencing (RNA-seq) data 
from 121 T-ALL samples, using our in-house pipeline (Genomon2.3.0: 
https://github.com/Genomon-Project/GenomonPipeline) (Supplementary Table 1)3.  In 
addition to previously reported fusions4-8 (Supplementary Table 2), we newly identified 
recurrent fusions involving SPI1 (also known as PU.1 encoding gene) in 5 samples, in which 
3’ exons of SPI1 (exons 3–5 or exons 2–5) were fused in-frame to 5’ exons of STMN1 (exons 
1–2) (n=2) or TCF7 (exons 1–3 or exons 1–2) (n=3), generating STMN1-SPI1 or TCF7-SPI1 
fusion gene, respectively (Fig. 1a and Supplementary Table 3).  An additional 2 cases 
with TCF7-SPI1 fusion were also found using RT-PCR in an independent validation cohort 
of 60 T-ALL cases, which were confirmed by RNA-seq.  Overall, SPI1 gene fusions were 
detected in 7 (3.9%) of 181 cases with pediatric T-ALL examined.  Genomic breakpoints 
were confirmed by targeted-capture sequencing in all SPI1 fusion-positive cases (Fig. 1b).  
The fusion-positive cases were either DN or CD8 SP and uniformly positive for CD2, CD3, 
CD5, and CD7.  Of note, HLA-DR expression, which is mostly negative in other T-ALL9, 
was positive in all SPI1 fusion-positive cases (Supplementary Fig. 1).  No cytogenetic 
abnormalities involving the SPI1 locus (11p11.2) had been reported in the fusion-positive 
cases, except for t(1;11)(p36;p11) in a patient with an STMN1-SPI1 fusion. 
 SPI1 is a member of the ETS family of transcription factors.  Originally identified as 
a transforming gene activated via a proviral integration of Friend erythroleukemia virus 
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(Spi1)10,11, SPI1 is expressed in various hematopoietic compartments, in which tightly 
regulated SPI1 expression is essential for the normal development of hematopoietic stem 
cells12,13-17,18-20.  During T-cell development, like other phase 1 genes involved in the 
precommitment to T-cells (such as LYL1, LMO2, GATA2, MEIS1, and BCL11A)21, SPI1 is 
expressed in prethymic progenitors and early T-cell precursor (ETP)22.  SPI1 expression 
then is shut off and replaced by the expression of TCF7 and other phase 2 genes (such as 
NOTCH1, RUNX1, GATA3, E2A, and BCL11B) during the transition from CD44+CD25+ (DN2) 
to CD44+CD25− T-cells (DN3), followed by the expression of phase 3 genes, such as ETS2, 
LEF1, and ID321,23.   
 The fusion-positive samples invariably showed markedly elevated SPI1 expression 
(Fig. 1c), most likely reflecting high-level fusion transcripts from the rearranged allele 
under the control of a heterologous promoter from TCF7 or STMN1, which was 
demonstrated to be highly expressed in the fusion-positive samples (Supplementary Fig. 
2).  The latter scenario was suggested by the disproportionally higher numbers of 
RNA-seq reads from 3’ SPI1 exons compared to those from 5’ SPI1 exons (Supplementary 
Fig. 2) and directly confirmed by the significantly increased number of fusion 
point-containing reads specifically found in the fusion-positive samples (Supplementary 
Fig. 3 and Supplementary Table 4). 
 Irrespective of the fusion partners, all predicted SPI1 fusion proteins retain the 
domains for DNA binding (ETS domain) but lack varying proportions of the 3’ end of SPI1 24.  
Thus, to assess the transcriptional potential of SPI1 fusions, we performed luciferase 
assay using Hela cells carrying a reporter containing a SPI1-responsive CSF1R (M-CSF 
receptor) promoter sequence25.  Compared to the Mock construct, STMN1- and 
TCF7-SPI1 fusion constructs showed markedly elevated (8- to 10-fold) luciferase activities, 
which were almost completely suppressed in mutants lacking the DNA binding ETS domain 
(Fig. 2a and Supplementary Fig. 4), suggesting that both SPI1 fusions retain the 
transcriptional activity inherent to SPI1.  Next, we evaluated the effect of SPI1 fusions 
on T-cell proliferation; DN T-cells from wild-type mice were transduced with fusion or 
wild-type SPI1 in an IRES-GFP construct, and 3.0×103 GFP-positive transduced cells were 
subjected to in vitro cell culture to examine the effect of both SPI1 fusions on cell 
proliferation.  As shown in Figure 2b, both wild-type and fusion SPI1-transduced cells 
showed significantly higher proliferation compared to Mock-transduced cells (P=2.1×10Ѹ2, 
1.8×10Ѹ3, and 1.3×10Ѹ2, respectively, the Student’s t-test).  We also investigated the 
effects of the SPI1 fusion on T-cell development using the TSt4-DLL1 co-culture 
system26,27, in which mouse DN1/2 thymocytes (LinѸCD44+) were transduced with either 
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wild-type or each fusion SPI1 and cultured on TSt4-DLL1 stromal cells.  As shown in 
Figure 2c-f, both STMN1- and TCF7-SPI1-transduced cells and wild-type SPI1-transduced 
cells showed differentiation block during DN T-cell development: there were significantly 
reduced numbers of DP, SP (CD4+ and CD8+), and DN4 T-cells, which were accompanied 
by an increase in DN, especially immature DN T-cells (DN1/2), although the effects of 
STMN1-SPI1 fusion were milder compared to wild-type SPI1 and TCF7-SPI1 fusion.  To see 
the in vivo effects of SPI1 fusions on T-cell differentiation, mouse stem cells 
(CD105+Sca-1+; LTR-HSCs) were transduced with either a wild-type SPI1 or a TCF7-SPI1 
fusion construct, transplanted into lethally irradiated mice, and analyzed for their 
differentiation potential within the thymus.  In accordance with in vitro analysis, 
recipients of wild-type SPI1- and TCF7-SPI1 fusion-transduced cells showed significantly 
increased DN T-cells and reduced CD4-SP and CD8-SP T-cells, compared to the control 
mice, although the reduction in CD4-SP cells was not statistically significant in the 
animals transplanted with wild-type SPI1-transduced cells.  Differential counts of DN 
T-cells also showed similar trends found in in vitro analysis; an increase in immature DN 
fractions (DN1/DN2) and a reduction in a more mature fraction (DN4).  Moreover, the 
recipients of fusion-transduced cells exhibited a significantly higher proportion of 
immature CD8 single-positive T-cells (CD4−CD8+CD24+TCRE−) (Supplementary Fig. 5). 
 To further characterize SPI1 fusion-positive T-ALL, we performed gene expression 
profiling of 123 T-ALL patients, including 2 additional fusion-positive cases.  Using 
consecutive two-step unsupervised consensus clustering, we obtained 5 stable clusters 
(Fig. 3 and Supplementary Figs. 6 and 7).  Among these, 4 clusters largely 
recapitulated distinct T-ALL subtypes characterized in previous studies by an ETP, high 
TAL1 expression (TAL1-related), and mutually exclusive expression of TLX1 and TLX3 
(TLX-related) (Fig. 3 and Supplementary Figs. 6 and 7)28,29.  The TAL1-related cluster 
was further classified into two stable subclusters, which conform to TAL1-RA and TAL1-RB 
according to the previous literature29, in regard to their immunophenotypic 
characteristics.  However, the remaining cluster was newly identified and exclusively 
consisted of the 7 SPI1 fusion-positive cases.  In terms of their characteristic gene 
expression pattern, SPI1 fusion-positive cases showed a phenotype mimicking the normal 
DN3-4 T-cells30, which was distinct from that of other clusters (Supplementary Fig. 8).  
Compared to ETP-ALL cases, these SPI1 fusion-positive patients typically showed reduced 
expression of the phase 1-specific transcription factor genes implicated in early T-cell 
development31.  An exception for this was the aberrant expression of SPI1 and 
SPI1-regulated genes (MEF2C and HHEX)32-34, which should be ascribed to the relevant 
gene fusions.  Of interest in this regard was aberrantly elevated expression of FLT3 and 
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KIT in the SPI1 fusion cluster, which have also been reported to be regulated by SPI1 
(Supplementary Figs. 9 and 10)35,36.  In contrast, ETP-ALL typically lacks expression of 
the phase 2/3-related genes, which were largely upregulated in SPI1 fusion-positive cases.  
Unlike TLX-related and TAL1-RA/RB cases, which are largely thought to conform to DP 
T-cells, none of the SPI1 fusion-positive cases showed overexpression of HOXA9, 
TLX1/TLX3, and TAL1 (Supplementary Fig. 8). 
 Genetic alterations in 121 T-ALL cases including 7 SPI1 fusion-positive cases were also 
investigated, using targeted-capture sequencing of 158 commonly mutated genes in 
pediatric ALL (see Online Methods), which were determined based on the analysis of the 
whole exome sequencing data from the Therapeutically Applicable Research to Generate 
Effective Treatment project (Supplementary Table 5–7).  In line with previous 
reports2,37-39, NOTCH1 (74%) and CDKN2A (73%) were by far the most frequently affected 
genes in T-ALL, although the frequency of CDKN2A lesions was characteristically lower in 
ETP-ALL than other T-ALL subtypes (Supplementary Fig. 9) (P=1.8×10-9, the Fisher’s 
exact test).  Other frequently mutated genes (>10%) included PHF6, FBXW7, PTEN, 
DNM2, USP7, NRAS, JAK3, WT1, and RUNX1 (Fig. 4a), which had previously been reported 
in T-ALL8,31,40-47 except for USP7.  The distribution of these genetic alterations 
substantially differed between T-ALL subtypes, conferring a unique mutational profile to 
each subtype (Fig. 4b).  As shown in previous reports31,44, ETP-ALL was characterized by 
frequent mutations in GATA3, RUNX1, NRAS, ETV6, and the epigenetic regulators, and 
rare CDKN2A deletions.  Frequent mutations in these epigenetic regulators were also 
found in TLX-related T-ALL, in which an especially high frequency of PHF6 and WT1 
mutations were among the unique mutational features.  The TAL1-RA and -RB29 were 
distinguished not only by their unique gene expression, but also by gene mutations; 
TAL1-RA is characterized by the paucity of these mutations commonly found in TAL1-RB, 
except for frequent PTEN and USP7 abnormalities.  Frequent mutations in USP7, which is 
involved in deubiquitination of PTEN48, were newly identified in this particular subtype of 
T-ALL.  In contrast, TAL1-RB showed frequent mutations in NOTCH1/FBXW7, 
transcription factors, RAS pathway genes, and epigenetic regulators.  Although their 
small sample size precluded accurate evaluation, SPI1 fusion-positive T-ALL shared 
several genetic abnormalities with other T-ALL subtypes2,37,49, such as frequent 
NOTCH1/FBXW7 mutations (6/7) and CDKN2A deletions (6/7), while other mutations 
commonly found in other T-ALL subtypes did not seem to be frequent, except for altered 
RAS pathway genes, which were found in 4 (57%) cases with SPI1 fusions (Supplementary 
Fig. 9). 
 Finally, we evaluated the effect of SPI1 fusions on the patients’ clinical outcomes 
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(Fig. 5).  Compared to SPI1 fusion-negative cases, SPI1 fusion-positive cases showed a 
significantly shorter overall survival with a median survival of 2.2 years (hazard ratio 
[HR]=6.05, 95% confidential interval [95%CI]: 2.4−15.1, log-rank P=1.12×10-8); 6 of 7 cases 
died within 3 years after diagnosis due to early relapse (Fig. 5a,d).  The survival was 
shorter compared to that of patients with other fusions or other clusters, respectively 
(log-rank P=5.12×10-4, 3.17×10-5) (Fig. 5b,c).  In multivariate analysis, SPI1 fusion status 
was shown to be an independent predictor of survival in pediatric T-ALL (Table 1), 
indicating a possible link between SPI1 fusions and an aggressive disease phenotype. 
 SPI1 needs to be downregulated in the DN3 stage for normal thymocyte 
differentiation50.  Constitutive SPI1 expression in fetal thymocyte organ culture leads to 
a block in the development at the DN3 stage and favored differentiation into 
macrophage51.  In SPI1 fusion-positive cells, functionally active SPI1 (fusion) expression 
is thought to be maintained during the transition from DN2/DN321,52 and DN/DP52, where 
TCF7 and STMN1 are expressed, respectively.  In fact, RNA-seq data from these 
fusion-positive samples confirmed a markedly elevated expression of full length TCF7 and 
STMN1 transcripts, together with those fused with SPI1 sequences, while the 
transcription from the wild-type SPI1 allele was silenced (Supplementary Fig. 2).  Also 
interesting in this point of view is a recent report describing a T-ALL case, in which SPI1 
was translocated to the BCL11B locus and overexpressed from an a promoter of BCL11B, a 
gene expressed at the DN2/DN3 stage (Supplementary Fig. 11)33.  Therefore, it is 
postulated that ectopic SPI1 expression during the DN2/DN3 transition should cause a 
differentiation block at the DN3 stage, contributing to T-cell leukemogenesis.  In 
accordance with this, SPI1 fusion-positive leukemic cells showed a DN or a CD8-SP 
phenotype and a gene expression profile that conformed to DN3−DN4 T-cells, and 
therefore is thought to be more immature than TAL1- and TLX-related subtypes but more 
differentiated than ETP (Supplementary Fig. 9).  To support this, upregulated SPI1 
expression in the mice lacking the SPI1 upstream regulatory element, which normally 
suppresses SPI1 expression in T-cells, also causes an impaired transition to the DN3 stage 
and even resulted in a high frequency of T-cell lymphoma50,53.   
In conclusion, we have described novel recurrent fusions involving SPI1 in pediatric 
T-ALL.  Exhibiting unique cytological and gene expression profiles, SPI1 fusion-positive 
T-ALL had a uniformly dismal clinical outcome.  To the best of our knowledge, these are 
the first genetic lesions associated with a very poor prognosis in pediatric T-ALL, although 
their impacts on survival need to be confirmed in additional cases.  Patients with SPI1 
fusions seem to be incurable with current standard chemotherapy, which underscores the 
importance of detecting this subset of patients for more intensive or alternative 
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therapies.  In this regard, RAS pathway mutations and aberrant expression of FLT3 and 
KIT associated with SPI1 fusion-positive T-ALL are of interest, which could be potentially 
targeted for therapeutics, although further studies would be warranted. 
 
URLs. Genomon2, http://genomon.readthedocs.io/ja/latest/index.html; Integrative 
Genomics Viewer (IGV), https:// www.broadinstitute.org/igv/. 
 
METHODS 
Methods and any associated references are available in the online version of the paper. 
 
Accession codes.  Sequencing data have been deposited in the DNA Data Bank of Japan 
(DDBJ) under accession JGAS00000000090.  
 
Note: Supplementary information is available in the online version of the paper. 
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Figure 1. SPI1 fusions in pediatric T-ALL. 
(a) Schematic representation of SPI1 fusions.  TAD: transcription activation domain; 
PEST: proline, glutamic acid, serine, and threonine-rich domain; ETS: E26 
transformation-specific domain.  (b) Breakpoints of SPI1 rearrangements detected by 
target capture sequencing are indicated by arrows.  (c) Comparison of SPI1 expression 
levels between SPI1 fusion-positive (n=7) and negative (n=116) cases, where normalized 
read counts mapped to SPI1 exons 1-5 are plotted.  The P-value was calculated using the 
Wilcoxon rank-sum test.   The mean and the 25th and 75th percentiles are also 
indicated in box plots and the whiskers extend up to 1.5 times the interquartile range.   
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Figure 2. Functional impacts of SPI1 fusions. 
(a) SPI1 transcriptional activities for different SPI1 constructs (see Supplementary Fig. 4 
for each construct, n=3 each) as measured by luciferase reporter assay using the reporter 
vector contained the CSF1R (M-CSF receptor) promoter region with PU.1 binding site. (b) 
In vitro growth of DN1 T-cells transduced with SPI1, STMN1-SPI1, and TCF7-SPI1 (type 1). 
Cell counts at indicated time-points are presented (n=3 each) with P-values (the Student 
t-test).  (c-f) The effect of SPI1 fusions on in vitro T-cell differentiation as evaluated by 
TSt-4/DLL1 co-culture assays.  Cell surface expression of CD4/CD8 in total GFP-positive 
cells (c) and that of CD25/CD44 in GFP-positive DN T-cells (e) are plotted for each SPI1 
construct as indicated.  The fractions (in %) of DN, DP, CD4 and CD8 SP cells among total 
GFP-positive cells and those of DN1/2, DN3, and DN4 cells (f) are compared between 
different SPI1 constructs with corresponding P-values (the Student’s t test): * P<0.05, ** 
P<0.01, *** P<0.001. 
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Figure 3. Gene expression clusters in 123 T-ALL based on the consecutive two-step 
unsupervised consensus clustering. 
Two stable clusters (TAL1 and non-TAL1) identified by the initial analysis (in 
Supplementary Fig. 6) are further divided into 5 subclusters; three (SPI1 fusion, ETP, and 
TLX-related) from the non-TAL1 cluster (a) and two (TAL1-RA and TAL1-RB) from the high 
TAL1 expression cluster (TAL1 cluster) (b).  Gene expression profile of these 5 clusters 
are shown in the bottom panels. The expression levels of core transcription factors 
relevant to T-cell development/differentiation are shown in the top panels and also 
indicated on the right.  Genetic alterations involving SPI1, TAL1, TLX1 and TLX3, as well 
as MLL family genes characteristic of these clusters are also indicated. 
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Figure 4. Gene mutations in different T-ALL expression subtypes. 
(a) Frequencies of recurrent mutations and copy number variations (CNVs) identified by 
targeted capture sequencing.  Mutation are categorized in indicated colors, where 
“Multiple” means gene abnormalities of two mutations or a mutation with a CNV.  (b) 
Gene mutations and CNVs among different T-ALL expression subtypes (n = 121).   Cases 
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are grouped according to the expression clusters as indicated.  Expression signatures of 
core transcription factors (TF), fusion status, significant mutations of known 
leukemia-related genes, and focal CNVs are also indicated together with clinical 
outcomes.  MLL in “Fusion” lanes includes KMT2A-MLLT1/MLLT6/TNRC18, 
PICALM-MLLT10, and SET-NUP214.  The color for each type of genetic alteration is 
defined below, where “Multiple” means gene abnormalities of two mutations or a 
mutation with a fusion. 
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Figure 5. Clinical impact of SPI1 fusions in T-ALL. 
Kaplan-Meier survival curves of overall survival (OS) (a-c) and relapse free survival (RFS) 
(e-f) for patients with and without a SPI1 fusion (a, d), for those having indicated gene 
fusions and those with no known fusions (b, e), and for different expression clusters.  
P-values are based on the log-rank test (c, f). 
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Table 1. Univariate and multivariate analysis of overall survival according to the SPI1 
fusion group and selected variables 
 
HR, hazard ratio; WBC, white blood cell count; PSL, prednisolone; PPR, PSL poor responder; PGR, 
PSL good responder; CNS, central nervous system 
 
  
 Univariate Multivariate 
 HR 95% CI P value HR 95% CI P value 
SPI1 fusion       
SPI1 fusion-positive vs. 
 SPI1 fusion-negative 
6.05 2.42-15.13 1.16 × 10-4 8.66 2.60-28.78 4.28 × 10-4 
Age (y.o.)       
≥10 vs. <10 0.67 0.32-1.40 0.290 0.97 0.38-2.48 0.95 
Sex       
Male vs. female 2.72 1.05-7.01 0.039 3.63 1.07-12.33 0.04 
WBC (/μl)       
≥ 10 x 106 vs. < 10 x 106 1.88 0.92-3.86 0.083 1.24 0.50-3.33 0.64 
PSL response       
PPR vs. PGR 1.30 0.61-2.76 0.50 1.72 0.74-3.99 0.21 
CNS involvement       
CNS 3 vs. CNS 1 or 2 1.64 0.63-4.29 0.31 1.19 0.41-3.46 0.75 
Mediastinal mass       
Yes vs. No 1.41 0.67-2.97 0.46 1.30 0.56-2.98 0.54 
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ONLINE METHODS 
Patients and materials.  A total of 181 cases with pediatric T-ALL were enrolled in this 
study (Supplementary Table 1).  These cases included two large cohorts from Tokyo 
Children's Cancer Study Group (TCCSG) and Japan Association of Childhood Leukemia 
Study (JACLS) and cases from various hospitals.  Peripheral blood (PB), bone marrow 
blood (BM), lymph node, or other infiltrated tissue samples were collected from patients 
after receiving written informed consent according to protocols approved by the Human 
Genome, Gene Analysis Research Ethics Committee of the University of Tokyo, and other 
participating institutes.  Matched normal samples from BM or PB at complete remission 
were available in 31 cases. 
 
Next-generation sequencing.  Next-generation sequencing was performed using the 
Illumina HiSeq 2000 or 2500 platform with a standard 100-bp paired-end read protocol, 
according to the manufacturer’s instruction54.  
 
Targeted-capture sequencing.  Among the 123 cases of RNA-seq performed, DNA was 
available in 121 cases and following targeted capture sequencing was performed.  
Targeted capture was performed using a SureSelect custom kit (Agilent Technologies), 
according to the manufacturer’s protocol3,55,56, for which 158 genes and regions were 
selected for the custom bait library (Supplementary Table 5), according to the following 
criteria on the basis of the whole exome sequencing data obtained from TARGET data of 
566 ALL cases (T-ALL 196 cases, B-ALL 367 cases) (dbGaP accession number; phs000464): 
(i) genes significantly mutated (q value < 0.1) in MutSigCV analysis57; (ii) genes or regions 
reported to be mutated in T-ALL or other T-cell lymphoma; (iii) TCR signaling–associated 
genes with somatic mutations occurring in one or more patients; (iv) intron or intergenic 
region of TCF7, STMN1 and SPI1; (v) enhancer region of TAL1; and (vi) 3′UTR region of 
NOTCH1.  Sequence alignment and detection of mutations and structural variations 
were performed using our in-house pipelines (Genomon v.2.3.0), where reads that had 
either a Mapping Quality score of <25, a BaseQuality score of <30 or five or more 
mismatched bases were excluded from the analysis.  Relevant somatic mutations were 
called and filtered by excluding (i) synonymous mutations and variants without complete 
ORF information; (ii) known variants listed in the 1000 Genomes Project (May 2011 
release), NCBI dbSNP build 131, National Heart, Lung, and Blood Institute (NHLBI) Exome 
Sequencing Project (ESP) 5400, the Human Genome Variation Database (HGVD; October 
2013 release) or our in-house SNP database; (iii) variants present only in unidirectional 
reads; (iv) variants occurring in repetitive genomic regions; (v) variants with a VAF <0.1; 
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(vi) variants with less than five supporting reads in tumor samples; (vii) all variants found 
in non-paired normal samples (n=30) showing allele frequencies >0.0025; and (xiii) all 
variants in paired samples showing VAF ≥0.1 in the normal sample.  We used stringent 
criteria for mutation calling, requiring a P value (by EBCall58) of <10−4 and the Fisher’s P 
value of <10−2.  Candidate mutations were further filtered by removing all missense SNVs 
with a VAF of 0.4–0.6 in copy-neutral regions, except for some pathogenic SNVs registered 
in the Catalogue of Somatic Mutations in Cancer (COSMIC) v70 as hematopoietic and 
lymphoid tissues or showed “H” in Mutation Assessor.  Putative structural variations 
were manually curated and further filtered by removing those with (i) less than four 
supporting reads in tumor samples; (ii) a VAF of <0.10 in tumor samples; and (iii) all 
variants found in normal samples.  Finally, mapping errors were removed by visual 
inspection on the Integrative Genomics Viewer (IGV) browser. 
 
Validation of mutations detected by Targeted-capture sequencing.  To confirm the 
somatic mutations detected in targeted-captured sequencing, we conducted PCR-based 
deep sequencing (depth≥1,500×) using matched normal samples (n=31).  To enable the 
random reading of targeted sequences, we first amplified the target sequences using 
primers tagged with NotI cleavage sites, and the products were then ligated and 
fragmented for deep sequencing as described previously59,60.  In total, 95 of 104 (91.3%) 
true-positive somatic variants were detected with a sensitivity of 96.9% (95/98). 
 
Mutation analysis.  The significance of the mutations in each gene was evaluated by 
calculating type I error under the null hypothesis that all the non-silent mutations were 
passenger changes, assuming a Poisson distribution with a uniform background mutation 
rate (λ).  We employed λ=0.21 mutation/Mb observed in whole exome sequencing data 
from the TARGET project.  After calculating the type I errors for 158 genes, significantly 
mutated genes (q<0.1) were estimated according to standard methods of 
Benjamini-Hochberg. 
 
RNA sequencing.  In 123 samples for which high-quality RNA (RNA integrity number>5.5) 
were available, libraries for RNA sequencing were prepared using the NEBNext Ultra RNA 
Library Prep kit for Illumina (New England BioLabs) or TruSeq RNA Library Preparation Kit 
v2 (Illumina).  Fusion transcripts were detected by Genomon-fusion or Genomon v.2.3.0 
and filtered by excluding fusions (i) mapped to repetitive regions; (ii) with less than four 
spanning reads; (iii) occurring out of frame; or (iv) with junctions not located at known 
exon–intron boundaries.  Normalized count data obtained by the variance-stabilizing 
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transformation (VST) of the R package DESeq2 were subjected to clustering analysis.  
Cluster stability was ascertained via consensus clustering with 1,000 iterations using the R 
package ConsensusClusterPlus.  Heatmaps were generated by pheatmap 1.0.7 using VST 
count data.  Differentially expressed genes were extracted using the R package DESeq2. 
 
Fusion transcript validation and screening.  All candidate in-frame fusion transcripts 
were validated by RT-PCR (Supplementary Table 2).  In an additional 60 cases as 
discovery cohort, TCF7-SPI1 and STMN1-SPI1 fusion transcripts were screened by RT-PCR 
and Sanger sequencing.   
 
Genomic copy number variations (CNVs).  All samples (n=121 samples) examined by 
targeted-capture sequencing were analyzed for genomic copy numbers using signal data 
calculated from sequence reads of T-ALL and control samples.  These analyses were 
implemented by in-house pipeline CNACS61.  The depths were calculated from the 
weighted sum of the fragments accounting for length and GC-biases during sequencing 
library amplification.  The depths were compared to those of pooled controls.  
Genomic copy number was estimated from the obtained depth ratios using circular binary 
segmentation method with the DNA copy package in R.  Allelic imbalance was assessed 
by the allele frequencies of the heterozygous SNPs covered by >50 reads.  When these 
criteria were applied to CDKN2A, CDKN2B, and PTEN for validation in matched 78 samples 
of available SNP array data (data not shown), 54 of 60 (90.0%) samples with true-positive 
homo/heterozygous loss were detected with a sensitivity of 87.1% (54/62). 
 
Flow cytometry analysis of leukemic cell samples.  FACS data of 91 cases were 
available in 123 cases with RNA sequencing analysis (Supplementary Fig. 1).  FACS 
analyses were performed at central institutes of TCCSG and JACLS or at each institute. 
 
Survival analysis.  Survival data were available for 120 patients with pediatric T-ALL 
having RNA sequencing data.  Overall survival (OS) was calculated from the date of 
diagnosis to death by any cause, and relapse-free survival (RFS) was calculated from 
diagnosis until first event (failure to achieve remission (calculated as an event at time=0 
day), relapse, secondary malignancy, or death by any cause) or last follow-up.  The 
Kaplan–Meier method was used to estimate OS and RFS, and the log-rank test was used to 
assess the differences in OS between the patient groups (R package survival). 
 
Statistical analysis.  Statistical analyses were performed using R 3.2.0 software.  For 
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functional assays, statistical significance was assessed by Student’s two-tailed t-test, and 
values were considered statistically significant at P<0.05. 
 
Luciferase assays.  Hela cells were collected 24 h after transfection and assayed for 
M-CSF receptor luciferase activity25 using the Dual-Luciferase Reporter Assay System 
(Promega).  The M-CSF receptor reporter vector was kindly provided by H. Hirai 
(Department of Transfusion Medicine and Cell Therapy, Graduate School of Medicine, 
Kyoto University, Kyoto, Japan).  Firefly luciferase activity was normalized by Renilla 
luciferase activity (pRL-SV40 vector) in each sample and was presented relative to the 
activity in Mock-transfected cells.  Constructs for luciferase assay are shown in 
Supplementary Figure 4. 
 
DN thymocyte culture.  We purified Lineage marker (Gr-1, Mac-1, Ter-119, B220, CD4, 
CD8α, γδTCR, CD3, CD11c, and NK1.1)- CD44+ CD25Ѹ DN1 and CD44+ CD25+ DN2 cells from 
mouse thymus and transduced them with indicated retroviruses on TSt-4/DLL1 stromal 
cells supplemented with 20 ng/ml of SCF, IL-7, and Flt3L.  At day 3 post-transduction, we 
sorted transduced cells expressing GFP, plated them on TSt-4/DLL1 stromal cells and 
monitored their growth in the presence of 20 ng/ml of SCF, IL-7, and Flt3L in triplicate 
and their growth was monitored at day 7, 14 and 21.  To evaluate the impact of 
transduced genes on differentiation of DN1/2 cells, sorted GFP+ cells were cultured on 
TSt-4/DLL1 stromal cells in the presence of 1 ng/ml of SCF, IL-7, and Flt3L for 7 days, 
stained with anti-CD45.2, anti-CD4, and anti-CD8, or anti-CD45.2, Lineage marker 
mixture, anti-CD25, and anti-CD44, and subjected to flow cytometric analyses.  Fraction 
of GFP positive cells is shown in Supplementary Figure 12 
 
Isolation of adult long-term repopulating hematopoietic stem cells (LTR-HSCs).  
According to previously described methods62,63, hematopoietic progenitors were 
harvested from 6- to 10-week-old female C57BL/6 mice 4 days after i.p. administration of 
150 mg/kg 5-fluorouracil (5-FU) and isolated using lymphoprep (Axis-Shield).  The MSCV 
IRES GFP, pMYs TCF7-SPI1, or wild-type SPI1 vector was transfected using 
polyethylenimine into Plat-E cells, an ecotropic packaging cell line.  Supernatants 
containing high titers of retrovirus were collected at 48 and 72 h and concentrated using 
Retro-X Concentrator (TAKARA-Clontech) and used to infect the isolated LTR-HSCs.  
Infection was performed in Retronectin-coated plate with 4 μg/mL protamine.  
Hematopoietic progenitors were cultured overnight in αMEM supplemented with 20% FCS 
and 50 ng/ml of each of mouse SCF (R&D systems #455-MC-010), human IL-6 
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(PEPROTECH#200-06), human FLT3 ligand (PEPROTECH#250-31L), and human 
thrombopoietin and infected with retrovirus particles at second day in αMEM 
supplemented with the same FCS and cytokines, using 24-well dishes coated according to 
the manufacturer’s recommendations with Retronectin.  60 h after infection with 
retrovirus, LTR-HSCs were transplanted into 6- to 10-week-old C57BL/6 male mice that 
received myeloablative conditioning with 9.5 Gy of total body irradiation 6 h before BMT.  
The mice received ad libitum drinking water containing 1 mg/ml neomycin trisulfate salt 
hydrate (SIGMA) and 100 U/ml polymyxin B sulfate salt (SIGMA).   Samples from the 
thymus were stained using 5–6 color combination of antibodies.  Data were acquired on 
BD LSRFORTESSA (Becton Dickinson) and analyzed using FACS DIVA software.  The 
following antibodies were purchased from Biolegend and eBioscience: PE Anti-Mouse 
CD19(1D3), Ly-6G/Ly-6C(Gr-1)(RB6-8C5), TER-119/Erythroid Cells (TER-119), 
NK-1.1(PK136), CD11b(M1/70), and CD45R/B220(RA3-6B2).  Fraction of GFP positive 
cells is shown in Supplementary Figure 13.  Experiments were performed in a specific 
pathogen–free unit in the vivarium of Tokyo Medical and Dental University. Experimental 
and animal care protocols were approved by the Tokyo Medical and Dental University 
animal care and use committee (protocol numbers 017012A). 
 
Expression array analysis in normal T cell development.  For the analysis of selected 
gene expression profiling in normal T cell development, public expression data submitted 
under GEO accessions GSE22601 (Affymetrix Human Genome U133A Array) was used.  
Replicate data in Series Matrix File (RMA normalized processed data) were converted to 
log 2 mean value.  
 
Data availability.  All sequencing data that support the findings of this study have been 
deposited in the in the DNA Data Bank of Japan (DDBJ) and are accessible through the 
DDBJ accession number JGAS00000000090.  All other relevant data are available from 
the corresponding authors on request. 
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